Conference Call with Fortis Healthcare Management and Analysts on Q4FY25 & Full Year Performance and Outlook. Listen to the full earnings transcript.
Conference Call with Solar Industries India Management and Analysts on Q4FY25 & Full Year Performance and Outlook. Listen to the full earnings transcript.
Conference Call with Max Healthcare Institute Management and Analysts on Q4FY25 & Full Year Performance and Outlook. Listen to the full earnings transcript.
Healthcare Facilities company Fortis Healthcare announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Consolidated Revenues up 12.4% to Rs 2,007 crore Operating EBITDA up 14.3% to Rs 435 crore, 21.7% Margin (vs Q4FY24 at 21.3%) Hospital Business Revenues up 14.2% to Rs 1,701 crore Operating EBITDA up 11.7% to Rs 372 crore, 21.9% Margin (vs Q4FY24 at 22.4%) FY25 Financial Highlights: Consolidated Revenues up 12.9% to Rs 7,783 crore Operating EBITDA up 25.3% to Rs 1,588 crore, 20.4% Margin (vs FY24 at 18.4%) Hospital Business Revenues up 14.8% to Rs 6,528 crore Operating EBITDA up 26.6% to Rs 1,339 crore, 20.5% Margin (vs FY24 at 18.6%) Commenting on the results for the quarter and the year, Ashutosh Raghuvanshi, MD and CEO, Fortis Healthcare stated, “We have witnessed another year of healthy growth and margin improvement. Noticeable developments during the year included the successful acquisition of the ‘Fortis’ brand and trademarks and our foray into Jalandhar with the signing of definitive agreements in February 2025 to acquire the Shrimann Superspecialty Hospital. The transaction enables us to further strengthen our presence in the Punjab region from approximately 800 beds across four facilities to over 1,000 beds. Aligned to our focus on portfolio rationalization, we divested the business operations of Richmond Road Hospital, Bengaluru in December 2024. Given the strength of our balance sheet, we continue to actively pursue further inorganic growth opportunities in our focus geographic clusters.” He further added “In FY25, our hospital business contributed 84% to consolidated revenue compared to 82% in FY24. Revenue from focus specialties comprising Oncology, Neurosciences, Cardiac Sciences, Gastroenterology, Orthopedics and Renal Sciences grew 16% YoY and contributed 62% to overall hospital business revenues. The Company consolidated its shareholding in Agilus to 89.2% post the acquisition of 31.5% stake from the PE investors. We have witnessed a steady improvement in the diagnostics business EBITDA margins (excluding one-offs) at 22.0% in FY25 compared to 19.6% in FY24. The new brand is being well accepted and gaining prominence; placing the business in a better position to drive business expansion and enhance performance metrics.” Result PDF